Nyrada Inc. announced a new collaboration between Nyrada, WRAIR and UNSW for a preclinical program investigating Nyrada's lead preclinical neuroprotection compound. The Collaboration will examine the ability of Nyrada's lead neuroprotection compound to interrupt and minimise the excitotoxicity process responsible for secondary damage to the brain, which leads to doubling of the injury size in the days following TBI. Nyrada has signed a Collaborative Research and Development Agreement (CRADA) with WRAIR to enable the preclinical studies of Nyrada's candidate neuroprotective drug. Under the CRADA, efficacy studies in TBI models established at WRAIR will be undertaken. In addition, the arrangement enables Nyrada and WRAIR to jointly pursue non-dilutive funding to progress Nyrada's preclinical studies for the neuroprotection program.